Peer-influenced content. Sources you trust. No registration required. This is HCN.
Eyewire+
“This acquisition immediately advances Biogen’s ongoing transformation… with two approved, best-in-class medicines that complement our existing portfolio.” — Christopher Viehbacher, President and CEO, Biogen
Ophthalmology April 7th 2026
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS